Bentley Pharmaceuticals Acquires Rights to Market Osteoporosis Products in Spain.TAMPA, Fla.--(BW HealthWire)--Aug. 25, 1998--Bentley Pharmaceuticals Inc. (AMEX AMEX See: American Stock Exchange :BNT BNT Bentley Pharmaceuticals, Inc. (stock symbol) BNT Boston Naming Test (psychology) BNT Bermuda National Trust BNT Bulgarian National TV BNT Broadband Network Termination BNT Binary File Transfer ) Tuesday announced that its Spanish subsidiary, Laboratorios Belmac, has acquired the regulatory dossiers and the rights from Italfarmaco to register and commercialize two calcium products, Cimascal and Cimascal Forte D, in Spain. Cimascal is a calcium carbonate calcium carbonate, CaCO3, white chemical compound that is the most common nonsiliceous mineral. It occurs in two crystal forms: calcite, which is hexagonal, and aragonite, which is rhombohedral. product and Cimascal Forte D is a combination of calcium carbonate and Vitamin D vitamin D Any of a group of fat-soluble alcohols important in calcium metabolism in animals to form strong bones and teeth and prevent rickets and osteoporosis. It is formed by ultraviolet radiation (sunlight) of sterols (see steroid) present in the skin. , both of which are used for calcium therapy in osteoporosis, osteomalacia osteomalacia /os·teo·ma·la·cia/ (os?te-o-mah-la´shah) inadequate or delayed mineralization of osteoid in mature cortical and spongy bone; it is the adult equivalent of rickets and accompanies that disorder in children. and as a supplement during pregnancy. The terms of the transaction were not disclosed. "The acquisition of the rights to these products is a valuable addition to our vitamin supplement product portfolio. Over the last few years, primary health care providers have become aware of the significant challenge that osteoporosis represents to the elderly community," said Chairman and Chief Executive Officer Jim Murphy  Please see the discussion on the . "As the population ages, it is becoming apparent that proactive treatment with products like Cimascal and Cimascal Forte D can substantially alleviate the problems associated with osteoporosis. Both of the products are pleasant tasting and we believe they will be well received by the market place. "According to IMS (1) See IP Multimedia Subsystem. (2) (Information Management System) An early IBM hierarchical DBMS for IBM mainframes. IMS was widely implemented throughout the 1970s under MVS and continues to be used under z/OS. , the market for calcium products in Spain is approximately $28 million annually. This market is projected to double by the year 2000. One of our goals over the next three years is to position our aggressive sales force to capture a significant portion of this rapidly expanding market. We expect to begin marketing these products once regulatory approval has been obtained and are hopeful that will occur within the next 12 months." Bentley Pharmaceuticals is an emerging international pharmaceutical company that leverages the competitive advantage of its manufacturing facility in Spain with drug delivery technology to provide treatment for cardiovascular, gastrointestinal, neurological and infectious diseases. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement Safe Harbor Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: The statements which are not historical facts contained in this news release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, the ability to find effective market distribution channels, development of new products, regulatory approval processes, the impact of competitive products or pricing, unpredictability of patent protection, technological changes, the effect of economic conditions and other uncertainties detailed in the company's filings with the Securities and Exchange Commission.
CONTACT: Kinexsys, Newport Beach, Calif.
Timothy R. Forstrom, 714/520-7507
or
Bentley Pharmaceuticals, Tampa
Elaine Melia, 813/286-4401
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion